Literature DB >> 14715568

Decreased expression of the CD3zeta chain in T cells infiltrating the synovial membrane of patients with osteoarthritis.

Lazaros I Sakkas1, George Koussidis, Efthimios Avgerinos, John Gaughan, Chris D Platsoucas.   

Abstract

Osteoarthritis (OA) is a heterogeneous disease which rheumatologists consider to be noninflammatory. However, recent studies suggest that, at least in certain patients, OA is an inflammatory disease and that patients often exhibit inflammatory infiltrates in the synovial membranes (SMs) of macrophages and activated T cells expressing proinflammatory cytokines. We report here that the expression of CD3zeta is significantly decreased in T cells infiltrating the SMs of patients with OA. The CD3zeta chain is involved in the T-cell signal transduction cascade, which is initiated by the engagement of the T-cell antigen receptor and which culminates in T-cell activation. Double immunofluorescence of single-cell suspensions derived from the SMs from nine patients with OA revealed significantly increased proportions of CD3epsilon-positive (CD3epsilon+) cells compared with the proportions of CD3zeta-positive (CD3zeta+) T cells (means +/- standard errors of the means, 80.48% +/- 3.92% and 69.02% +/- 6.51%, respectively; P = 0.0096), whereas there were no differences in the proportions of these cells in peripheral blood mononuclear cells (PBMCs) from healthy donors (94.73% +/- 1.39% and 93.79% +/- 1.08%, respectively; not significant). The CD3zeta+ cell/CD3epsilon+ cell ratio was also significantly decreased for T cells from the SMs of patients with OA compared with that for T cells from the PBMCs of healthy donors (0.84 +/- 0.17 and 0.99 +/- 0.01, respectively; P = 0.0302). The proportions of CD3epsilon+ CD3zeta+ cells were lower in the SMs of patients with OA than in the PBMCs of healthy donors (65.04% +/- 6.7% and 90.81% +/- 1.99%, respectively; P = 0.0047). Substantial proportions (about 15%) of CD3epsilon+ CD3zeta-negative (CD3zeta-) and CD3epsilon-negative (CD3epsilon-) CD3zeta- cells were found in the SMs of patients with OA. Amplification of the CD3zeta and CD3delta transcripts from the SMs of patients with OA by reverse transcriptase PCR consistently exhibited stronger bands for CD3delta cDNA than for CD3zeta cDNA The CD3zeta/CD3delta transcript ratio in the SMs of patients with OA was significantly lower than that in PBMCs from healthy controls (P < 0.0001). These results were confirmed by competitive MIMIC PCR. Immunoreactivities for the CD3zeta protein were detected in the SMs of 10 of 19 patients with OA, and they were of various intensities, whereas SMs from all patients were CD3epsilon+ (P = 0.0023). The decreased expression of the CD3zeta transcript and protein in T cells from the SMs of patients with OA relative to that of the CD3epsilon transcript is suggestive of chronic T-cell stimulation and supports the concept of T-cell involvement in OA.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14715568      PMCID: PMC321327          DOI: 10.1128/cdli.11.1.195-202.2004

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  70 in total

1.  CCR5 is characteristic of Th1 lymphocytes.

Authors:  P Loetscher; M Uguccioni; L Bordoli; M Baggiolini; B Moser; C Chizzolini; J M Dayer
Journal:  Nature       Date:  1998-01-22       Impact factor: 49.962

2.  Changes in expression of signal transduction proteins in T lymphocytes of patients with leprosy.

Authors:  A H Zea; M T Ochoa; P Ghosh; D L Longo; W G Alvord; L Valderrama; R Falabella; L K Harvey; N Saravia; L H Moreno; A C Ochoa
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

3.  HLA-DP: a class II restriction molecule involved in epitope spreading during the development of multiple sclerosis.

Authors:  M Yu; R P Kinkel; B Weinstock-Guttman; D J Cook; V K Tuohy
Journal:  Hum Immunol       Date:  1998-01       Impact factor: 2.850

4.  Decreased expression of signal-transducing CD3 zeta chains in T cells from the joints and peripheral blood of rheumatoid arthritis patients.

Authors:  M Matsuda; A K Ulfgren; R Lenkei; M Petersson; A C Ochoa; S Lindblad; P Andersson; L Klareskog; R Kiessling
Journal:  Scand J Immunol       Date:  1998-03       Impact factor: 3.487

5.  Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts.

Authors:  R Ciubotariu; Z Liu; A I Colovai; E Ho; S Itescu; S Ravalli; M A Hardy; R Cortesini; E A Rose; N Suciu-Foca
Journal:  J Clin Invest       Date:  1998-01-15       Impact factor: 14.808

6.  Circulating CD8 T lymphocytes in human immunodeficiency virus-infected individuals have impaired function and downmodulate CD3 zeta, the signaling chain of the T-cell receptor complex.

Authors:  L A Trimble; J Lieberman
Journal:  Blood       Date:  1998-01-15       Impact factor: 22.113

7.  Altered pattern of TCR/CD3-mediated protein-tyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T cell receptor zeta chain.

Authors:  S N Liossis; X Z Ding; G J Dennis; G C Tsokos
Journal:  J Clin Invest       Date:  1998-04-01       Impact factor: 14.808

8.  The diagnostic value of perivascular infiltrates in muscle biopsy specimens for the assessment of rheumatoid vasculitis.

Authors:  A E Voskuyl; S G van Duinen; A H Zwinderman; F C Breedveld; J M Hazes
Journal:  Ann Rheum Dis       Date:  1998-02       Impact factor: 19.103

9.  T cells and T-cell cytokine transcripts in the synovial membrane in patients with osteoarthritis.

Authors:  L I Sakkas; C Scanzello; N Johanson; J Burkholder; A Mitra; P Salgame; C D Katsetos; C D Platsoucas
Journal:  Clin Diagn Lab Immunol       Date:  1998-07

10.  Interleukin 2 restores CD3-zeta chain expression but fails to generate tumour-specific lytic activity in tumour-infiltrating lymphocytes derived from human colorectal hepatic metastases.

Authors:  K F Yoong; D H Adams
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

View more
  8 in total

Review 1.  The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis.

Authors:  Jérémie Sellam; Francis Berenbaum
Journal:  Nat Rev Rheumatol       Date:  2010-10-05       Impact factor: 20.543

2.  Unicompartmental and bicompartmental knee osteoarthritis show different patterns of mononuclear cell infiltration and cytokine release in the affected joints.

Authors:  B Moradi; N Rosshirt; E Tripel; J Kirsch; A Barié; F Zeifang; T Gotterbarm; S Hagmann
Journal:  Clin Exp Immunol       Date:  2015-04       Impact factor: 4.330

Review 3.  Immune Contributions to Osteoarthritis.

Authors:  Erika Barboza Prado Lopes; Adrian Filiberti; Syed Ali Husain; Mary Beth Humphrey
Journal:  Curr Osteoporos Rep       Date:  2017-12       Impact factor: 5.096

Review 4.  Obesity, Inflammation, and Immune System in Osteoarthritis.

Authors:  Udhaya Nedunchezhiyan; Ibin Varughese; Antonia RuJia Sun; Xiaoxin Wu; Ross Crawford; Indira Prasadam
Journal:  Front Immunol       Date:  2022-07-04       Impact factor: 8.786

Review 5.  Recognition of Immune Response for the Early Diagnosis and Treatment of Osteoarthritis.

Authors:  Adrese M Kandahari; Xinlin Yang; Abhijit S Dighe; Dongfeng Pan; Quanjun Cui
Journal:  J Immunol Res       Date:  2015-05-03       Impact factor: 4.818

6.  Immune Mediators in Osteoarthritis: Infrapatellar Fat Pad-Infiltrating CD8+ T Cells Are Increased in Osteoarthritic Patients with Higher Clinical Radiographic Grading.

Authors:  Jirun Apinun; Panjana Sengprasert; Pongsak Yuktanandana; Srihatach Ngarmukos; Aree Tanavalee; Rangsima Reantragoon
Journal:  Int J Rheumatol       Date:  2016-12-14

7.  Investigation of candidate genes for osteoarthritis based on gene expression profiles.

Authors:  Shuanghai Dong; Tian Xia; Lei Wang; Qinghua Zhao; Jiwei Tian
Journal:  Acta Orthop Traumatol Turc       Date:  2016-11-18       Impact factor: 1.511

Review 8.  Human autoimmune diseases are specific antigen-driven T-cell diseases: identification of the antigens.

Authors:  Chris D Platsoucas; Emilia L Oleszak
Journal:  Immunol Res       Date:  2007       Impact factor: 4.505

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.